Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells

Journal of Clinical Investigation

Volumn 123, Issue 8, 2013, Pages 3459-3471

  Al Aidaroos, Abdul Qader Omer ^a   Yuen, Hiu Fung ^a   Guo, Ke ^a   Zhang, Shu Dong ^b   Chung, Tae Hoon ^c   Chng, Wee Joo ^c,d   Zeng, Qi ^a,e  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; METASTASIS ASSOCIATED PHOSPHATASE OF REGENERATING LIVER 3; PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CARCINOGENICITY; CELL GROWTH; CELL MIGRATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME REPRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTEIN TYROSINE PHOSPHATASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TREATMENT OUTCOME;

EID: 84881247984     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66824     Document Type: Article

References (65)

1. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7(11):833-846.
2. Saha S, et al. A phosphatase associated with metastasis of colorectal cancer. Science. 2001; 294(5545):1343-1346.
3. Laurent C, et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 2011;71(3):666-674.
4. Bessette DC, Wong PCW, Pallen CJ. PRL-3: a metastasis- associated phosphatase in search of a function. Cells Tissues Organs. 2007;185(1-3):232- 236.
5. Al-Aidaroos AQ, Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem. 2010; 111(5):1087-1098.
6. Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial- mesenchymal transition. Cancer Res. 2007;67(7):2922-2926.
7. Wang H, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell. 2010;18(1):52-62.
8. Wee S, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A. 2008; 105(35):13057-13062.
9. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
10. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19(13):3159-3167.
11. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12(8):553-563.
12. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003;4(7):397-406.
13. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62(14):4132-4141.
14. Ebi H, et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011;121(11):4311-4321.
15. Merlino GT, et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science. 1984;224(4647):417-4119.
16. Ciaccio MF, Wagner JP, Chuu CP, Lauffenburger DA, Jones RB. Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods. 2010;7(2):148-155.
17. Astsaturov I, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal. 2010;3(140):ra67.
18. Rojas M, Yao S, Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem. 1996;271(44):27456-27461.
19. Batzer AG, Rotin D, Ureña JM, Skolnik EY, Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol. 1994;14(8):5192-5201.
20. Rodrigues GA, Falasca M, Zhang Z, Ong SH, Schlessinger J. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol. 2000;20(4):1448-1459.
21. Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem. 2007;282(8):5413-5419.
22. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004;23(48):7957-7968.
23. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A. 1999;96(4):1415-1420.
24. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267(5205):1782-1788.
25. Okutani Y, et al. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene. 2001;20(45):6643-6650.
26. Ceresa BP, Vanlandingham PA. Molecular mechanisms that regulate epidermal growth factor receptor inactivation. Clin Med Oncol. 2008;2:47-61.
27. Haj FG, Markova B, Klaman LD, Bohmer FD, Neel BG. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem. 2003;278(2):739-744.
28. Sangwan V, et al. Protein tyrosine phosphatase PTP1B modulates early endosome fusion and trafficking of Met and EGF receptor tyrosine kinases. J Biol Chem. 2011;286(52):45000-45013.
29. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007;12(7):840-849.
30. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol. 2008;68(2):93-106.
31. Bos PD, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009; 459(7249):1005-1009.
32. Wehrle-Haller B, Imhof BA. Actin, microtubules and focal adhesion dynamics during cell migration. Int J Biochem Cell Biol. 2003;35(1):39-50.
33. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131-142.
34. Yip SC, et al. The distinct roles of Ras and Rac in PI 3-kinase-dependent protrusion during EGF-stimulated cell migration. J Cell Sci. 2007; 120(pt 17):3138-3146.
35. Bianco R, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003;22(18):2812-2822.
36. Yamasaki F, et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007;6(8):2168-2177.
37. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077- 3080.
38. [No authors listed]. Platinum complexes in cancer chemotherapy. Antibiot Chemother. 1978;23:99-112.
39. Khambata-Ford S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230-3237.
40. Baker JB, et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer. 2011;104(3):488-495.
41. Coldren CD, et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 2006;4(8):521-528.
42. Robertson SC, Tynan J, Donoghue DJ. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet. 2000;16(8):368.
43. Bennett H, et al. Signalling by EGF receptor in human cancers: Accentuate the positive, eliminate the negative. In: Haley J, Gullick W, eds. EGFR Signaling Networks in Cancer Therapy. New York, New York, USA: Humana Press; 2009:224-244.
44. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211-225.
45. Ferrari E, et al. Identification of new substrates of the protein-tyrosine phosphatase PTP1B by Bayesian integration of proteome evidence. J Biol Chem. 2011;286(6):4173-4185.
46. Fukada T, Tonks NK. Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling. EMBO J. 2003;22(3):479-493.
47. Suwaki N, et al. A HIF-regulated VHL-PTP- 1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med. 2011;3(85):85ra47.
48. Fukada T, Tonks NK. The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase. J Biol Chem. 2001;276(27):25512-25519.
49. Liu Y, et al. An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer. Gut. 2013;62(4):571-581.
50. Zhu S, Bjorge JD, Fujita DJ. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res. 2007;67(21):10129-10137.
51. Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct. 2011;2011:865819.
52. Liang F, et al. Translational control of C-terminal Src kinase (Csk) expression by PRL3 phosphatase. J Biol Chem. 2008;283(16):10339-10346.
53. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. In: Carpenter G, ed. The EGF Receptor Family. Nashville, Tennessee, USA: Academic Press; 2003:33-55.
54. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007;21(24):3214-3231.
55. Takano T, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-6837.
56. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
57. Zuber J, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25(15):1628-1640.
58. Mortlock AA, Barker AJ. Kinase inhibitors for cancer. In: Taylor JB, Triggle DJ, eds. Comprehensive Medicinal Chemistry II. London, United Kingdom: Elsevier Science Ltd.; 2007:183-220.
59. Daouti S, et al. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res. 2008;68(4):1162-1169.
60. Guo K, et al. Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget. 2012;3(2):158-171.
61. Guo K, et al. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res. 2006;66(19):9625-9635.
62. Sells MA, Chernoff J. Epitope-tag vectors for eukaryotic protein production. Gene. 1995;152(2):187-189.
63. Arias-Romero LE, et al. Activation of Src by protein tyrosine phosphatase 1B Is required for ErbB2 transformation of human breast epithelial cells. Cancer Res. 2009;69(11):4582-4588.
64. Li J, et al. Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clin Cancer Res. 2005;11(6):2195-2204.
65. Yuen HF, et al. RanGTPase: a candidate for Mycmediated cancer progression. J Natl Cancer Inst. 2013;105(7):475-488.